Skip to main content

Table 2 Mean differences of MDADI subscales according to clinical and treatment variables of participants

From: Dysphagia and its impact on the quality of life of head and neck cancer patients: institution-based cross-sectional study

Variable   MDADI (Mean ± SD)
All questions Composite mean Global Emotional Functional Physical
Time since diagnosis
 New 52.1 ± 17.1 51.9 ± 15.4 44.6 ± 24.3 55.9 ± 16.9 56.5 ± 17.9 47.4 ± 19.0
 6–12 months 52.9 ± 17.4 53.1 ± 16.2 46.7 ± 24.4 54.4 ± 18.9 55.8 ± 17.2 50.7 ± 18.9
 More than year ago 55.3 ± 16.6 55.1 ± 16.3 41.9 ± 20.2 60.1 ± 16.2 61.3 ± 17.4 50.2 ± 20.3
 P 0.729 0.333 0.707 0.389 0.389 0.749
Primary tumor site
 Oral cavity/Oropharyngeal 57.4 ± 20.8 57.4 ± 18.4 52.0 ± 28.1 59.3 ± 20.9 60.7 ± 20.5 54.5 ± 22.8
 Nasal cavity/Nasopharyngeal 55.0 ± 16.4 54.7 ± 16.1 43.9 ± 21.1 59.0 ± 16.4 59.9 ± 16.9 50.8 ± 19.8
 Larynx/ Hypo pharyngeal 47.2 ± 11.5 47.5 ± 11.2 38.1 ± 18.2 50.9 ± 13.8 51.9 ± 14.1 42.7 ± 12.2
 P 0.044* 0.040* 0.058* 0.086 0.084 0.045*
Tumor T stage
 Initial 57.5 ± 18.2 57.7 ± 15.8 50.7 ± 24.9 60.5 ± 18.4 61.8 ± 16.8 53.4 ± 20.8
 Advanced 50.6 ± 15.6 50.3 ± 15.3 40.3 ± 20.8 54.0 ± 16.4 54.9 ± 17.6 46.8 ± 17.9
 P 0.042* 0.019* 0.024* 0.067 0.049* 0.092
Type of carcinoma
 Squamous cell 53.0 ± 16.6 53.3 ± 15.8 44.4 ± 22.1 56.0 ± 17.8 57.2 ± 17.2 49.5 ± 18.8
 Adenocarcinoma 55.6 ± 19.5 54.7 ± 17.4 48.7 ± 25.5 58.3 ± 18.9 60.2 ± 20.2 51.5 ± 22.0
 Other 51.3 ± 15.1 51.2 ± 14.4 38.7 ± 23.3 56.7 ± 13.9 56.0 ± 15.0 45.8 ± 17.2
 P 0.730 0.803 0.425 0.874 0.725 0.676
Treatment modality
 Single modality treatment 50.5 ± 14.7 50.1 ± 14.0 40.9 ± 20.7 55.4 ± 15.9 55.7 ± 16.9 45.2 ± 16.7
 Multi-modality treatment 55.5 ± 18.3 55.8 ± 16.9 47.2 ± 24.5 57.5 ± 18.6 59.2 ± 17.9 52.6 ± 20.6
P 0.148 0.072 0.170 0.555 0.328 0.054
  1. t-test (for two groups comparison) and one-way ANOVA (for three and above group comparison) were employed, *Significant at p value less than 0.05